Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091879 · ClinicalTrials.gov registry record · NA
Preemptive Pharmacogenomics Testing Among Geriatric Patients
A NA study of Polypharmacy and Pharmacogenomic Testing, sponsored by Geisinger Clinic.
- Active
- Registry status
- NA
- Development phase
- 2,000
- Enrollment target
- 1
- Study location
NCT05091879: Active NA study of Polypharmacy and Pharmacogenomic Testing, sponsored by Geisinger Clinic.
NCT05091879 is a NA study of Polypharmacy and Pharmacogenomic Testing that is active but no longer recruiting, run by Geisinger Clinic. The registered enrollment target is 2,000 participants, above the 1,348-participant average among 11 other Polypharmacy trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091879, a NA study of Polypharmacy and Pharmacogenomic Testing, is active but no longer recruiting, sponsored by Geisinger Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, healthcare utilization, and costs of care.
Primary Outcome
The primary objective will be assessed by comparing the total number of patients with returned results in the electronic health record (EHR) with the total number of tested patients.
Conditions Studied
Interventions
- GENETIC Multigene pharmacogenomics test
Study Locations (1)
Pennsylvania
- Geisinger - Danville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT05091879 still lists
NCT05091879 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,348-participant average among 11 other Polypharmacy trials with a reported enrollment target (48% higher).
The record links to 2 conditions, with Polypharmacy appearing as the primary indexed condition, and to 1 intervention - of which Multigene pharmacogenomics test is the first listed.
NCT05091879 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05091879 about?
NCT05091879 is a clinical study titled "Preemptive Pharmacogenomics Testing Among Geriatric Patients". The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, healthcare utilization, and costs of care.
What is the current status of trial NCT05091879?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2023-03-28. Estimated completion is 2026-06.
What conditions does trial NCT05091879 study?
This clinical trial studies the following conditions: Polypharmacy, Pharmacogenomic Testing.
What interventions are being tested in trial NCT05091879?
The interventions under investigation include: Multigene pharmacogenomics test (GENETIC).
Who is sponsoring clinical trial NCT05091879?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05091879 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polypharmacy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05091879's enrollment target sits among peer trials
2,000 4th of 11 higher than 8 of 11 other Polypharmacy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polypharmacy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Medication Management in World Trade Center Responders
RECRUITING · NA
-
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
RECRUITING · NA
-
Effectiveness of PGx Testing
ACTIVE NOT RECRUITING · NA
-
Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial
ACTIVE NOT RECRUITING · NA
-
Pharmacist Intervention to Reduce Post-Hospitalization Utilization
ACTIVE NOT RECRUITING · NA
-
A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI